Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
Today, we are pleased to welcome a guest post from Jim Kremidas, Executive Director, Association of Clinical Research Professionals.
We have a talented clinical trial workforce dedicated to advancing biopharmaceutical research and development. They’ve proven their stunning capabilities by making phenomenal progress toward not just one, but several safe and effective COVID-19 vaccines in a matter of months. However, COVID-19 has shined a light on a decades-long problem: patients from diverse backgrounds are underrepresented and understudied in clinical research. One solution is to hire a more diverse clinical trial workforce. Minority patients tend to feel more trust toward minority health care providers. By increasing minority staff at investigator sites, we could attract more minority patients for trials.
According to the Centers for Disease Control and Prevention, Black communities are more than twice as likely to die from the coronavirus as white communities. Despite this staggering number, many companies conducting clinical vaccine trials struggled early on to ensure a minority presence. Clinical trials must better represent the entire patient population. It’s not just a moral question, though of course that is a major element. From a scientific perspective, a more diverse patient population will enhance the clinical trials, making the data stronger and more relevant.
We need to widen the pipeline of new talent to achieve that more diverse workforce. This is particularly critical at investigator sites in part because most people learn about a clinical trial from their health care practitioner, and studies show minority patients have better relationships with minority health care providers. More minority staff at investigator sites could mean greater participation by more minority patients in new trials.
In an effort to put this belief in action, the Association of Clinical Research Professionals (ACRP) Partners in Workforce Advancement (PWA) launched a new outreach campaign designed to raise awareness of clinical research as a career option among minority college students called the “Find Your Element” campaign. It began in February 2020 in Miami and the Research Triangle Park region of North Carolina, and soon expanded to Atlanta, Baltimore, San Francisco and Washington, D.C., in November 2020. Its goal is to help make investigator site staff and study participants more representative of the patient population. The pilot campaign will reach nearly 400,000 students currently enrolled in healthcare and life sciences programs at colleges and universities across those markets.
ACRP’s PWA is a multi-stakeholder, collaborative initiative to grow and diversify the clinical research workforce and set and support standards for workforce competence. PWA membership includes more than 30 organizations representing sponsors, contract research organizations, sites, regulatory agencies, academic institutions, suppliers and more. As of November 2020, the campaign has reached more than 22 million people and generated more than 134,000 visits to the campaign website where students can learn about the clinical research profession.
Additionally, we are proud to support PhRMA’s efforts in this space, in particular their recently released clinical trial diversity principles. Together, let’s ensure our clinical trial workforce—and, in turn, the people who participate in clinical trials—truly reflect the powerful diversity of our nation.
For more information, please visit the ACRP Partners in Workforce Advancement or phrma.org/equity.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
ICYMI: PhRMA submits comments to White House on artificial intelligence
New research: Industry sponsored clinical trials contribute billions to state economies
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Decentralized clinical trials and the future of drug development
Between hope and despair: Improving cancer outcomes
ICYMI: PhRMA CMO Dr. Michael Ybarra speaks with Dr. Fabian Sandoval about clinical trial diversity
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
PhRMA submits comments to OSTP on enhancing clinical trial diversity
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Traditional HTA methods treat everyone like the “average” patient
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Potential gene therapies bring hope to patients with sickle cell disease
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
PhRMA hosts first stakeholder workshop on clinical trial diversity
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA member companies share how they are improving clinical trial diversity
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Sharing rebates can improve access to medicines and increase health equity
PhRMA will continue to advocate for equity within our industry
Three ways the pharmaceutical industry can positively impact health equity
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
PhRMA awards $100,000 to fund projects that address health inequalities
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
COVID-19 Response: Supporting the frontline
America’s biopharmaceutical companies are working around the clock to beat coronavirus
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Clinical trials impact state economies
Examining the truth behind clinical trial costs
New report details the setbacks and challenges to Alzheimer’s research
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials
Bringing innovation to clinical trial design
EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing
Guest Post: Film chronicles clinical trials ‘paying it forward’
Biopharmaceutical industry policies aim to increase access to clinical trial data
Guest Post: The Clinical trial experience from a patient & researcher perspective
Guest Post: Patients as research partners - Rethinking patient access to clinical trial data
Guest Post: Spotlighting the heroes in clinical trials
Guest Post: Advancing oncology research through clinical trials
Clinical Trials Awareness Week: Celebrating the impact of clinical research
Driving innovation through collaboration
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
Increasing diversity at investigator sites could increase minority participation in clinical trials
Clinical Trials
Health Equity
Increasing diversity at investigator sites could increase minority participation in clinical trials
Increasing diversity at investigator sites could increase minority participation in clinical trials